This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
AxoGen, Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced that it will be presenting Monday, September 24, 2012 at the BioX – Life Sciences Exposition sponsored by Noble Financial Capital Markets at the University of Connecticut, Stamford Campus. Gregory G. Freitag, AxoGen’s Chief Financial Officer and Erick DeVinney, AxoGen’s Director of Clinical and Translational Science, will participate in a panel discussion entitled “The Explosion of a New Industry - Tissue Engineering & Biomaterials”.
“It is pleasure to participate in this aspect of the regenerative medicine discussion,” said Erick DeVinney. “The expansion of technology in the area of tissue engineering, including extracellular matrix scaffolds and cellular therapies, has continued and AxoGen is providing exciting new possibilities for treatment of peripheral nerve injuries. We are fortunate to be a leader in translating technology into impactful products that are used every day, and look forward to continuing to make advancements.”
Mr. Freitag will also give a Company presentation on AxoGen, Monday, September 24, 2012, at 3:30 PM Eastern Time. A live audio broadcast of Mr. Freitag’s conference presentation will be available on the Company’s website,
www.AxoGenInc.com. Following the live broadcast, a replay of the conference presentation will be available through the Company's website.
About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a regenerative medicine company dedicated to advancing the science of peripheral nerve repair and commercializing next generation surgical technologies. The Company’s portfolio of proprietary products and technologies offers new options for surgical nerve repair and reconstruction. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance
® Nerve Graft, the only commercially available processed nerve allograft nerve for bridging nerve discontinuities of 5mm to 70mm in length, AxoGuard
® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard
® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. For more information, visit our website at